EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers

Jianfei Qian, Qiang Wang, Liuling Xiao, Wei Xiong, Miao Xian, Pan Su, Maojie Yang, Chuanchao Zhang, Yabo Li, Ling Zhong, Siddhartha Ganguly, Youli Zu und 1 weitere

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jianfei Qian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Research in Hematological Malignancies, Houston Methodist Neal Cancer Center/Houston Methodist Research Institute, Houston M…. Hauptthemen laut MEDLINE: HLA-A2 Antigen, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Leukemia and Lymphoma Society Translational Research Award, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Targeted immunotherapy with monoclonal antibodies (mAbs) is an effective and safe method for the treatment of malignancies. Development of mAbs with improved cytotoxicity, targeting new and known tumor-associated antigens, therefore continues to be an active research area. We reported that Dickkopf-1 (DKK1) is a good target for immunotherapy of human cancers based on its wide expression in different cancers but not in normal tissues. As DKK1 is a secreted protein, mAbs binding directly to DKK1 have limited effects on cancer cells in vivo.

Methods

The specificity and antibody-binding capacity of DKK1-A2 mAbs were determined using indirect ELISA, confocal imaging, QIFIKIT antibody-binding capacity and cell surface binding assays. The affinity of mAbs was determined using a surface plasmon resonance biosensor. A flow cytometry-based cell death was performed to detect tumor cell apoptosis. Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays were used to evaluate the ability of DKK1-A2 mAbs to mediate ADCC and CDC activities against tumor cells in vitro. Flow cytometry data were collected with an FACSymphony A3 cell analyzer and analyzed with FlowJo V.10.1 software. Human cancer xenograft mouse models were used to determine the in vivo therapeutic efficacy and the potential safety and toxicity of DKK1-A2 mAbs. In situ TUNEL assay was performed to detect apoptosis in tumors and mouse organs.

Results

We generated novel DKK1-A2 mAbs that recognize the DKK1 P20 peptide presented by human HLA-A*0201 (HLA-A2) molecules (DKK1-A2 complexes) that are naturally expressed by HLA-A2 + DKK1 + cancer cells. These mAbs directly induced apoptosis in HLA-A2 + DKK1 + hematologic and solid cancer cells by activating the caspase-9 cascade, effectively lysed the cancer cells in vitro by mediating CDC and ADCC and were therapeutic against established cancers in their xenograft mouse models. As DKK1 is not detected in most human tissues, DKK1-A2 mAbs neither bound to or killed HLA-A2 + blood cells in vitro nor caused tissue damage in tumor-free or tumor-bearing HLA-A2-transgenic mice.

Conclusion

Our study suggests that DKK1-A2 mAbs may be a promising therapeutic agent to treat human cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA-A2 AntigenNeoplasmsHumansAnimalsMiceAntibodies, MonoclonalPeptidesImmunotherapyDisease Models, AnimalIntercellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

Antibodies, NeoplasmHematologic NeoplasmsImmunotherapyTranslational Medical Research

Substanzen

HLA-A2 AntigenAntibodies, MonoclonalPeptidesDKK1 protein, humanIntercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Center for Translational Research in Hematological Malignancies, Houston Methodist Neal Cancer Center/Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.
  • Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.
  • Department of Pathology and Genomic Medicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA.
  • Center for Translational Research in Hematological Malignancies, Houston Methodist Neal Cancer Center/Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA qyi@houstonmethodist.org.

Förderung

  • NCI NIH HHS
  • Leukemia and Lymphoma Society Translational Research Award
  • National Cancer Institute
  • Cancer Prevention & Research Institute of Texas (CPRIT) Recruitment of Established Investigator Award
  • Division of Cancer Prevention, National Cancer Institute
  • CPRIT High-Impact/High-Risk Research Award

Zitieren

APA

Qian, J., Wang, Q., Xiao, L., Xiong, W., Xian, M., Su, P., Yang, M., Zhang, C., Li, Y., Zhong, L., Ganguly, S., Zu, Y., & Yi, Q. (2024). Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008145

Vancouver

Qian J, Wang Q, Xiao L, Xiong W, Xian M, Su P, et al. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008145

BibTeX
@article{Qian2024,
  author = {Qian, Jianfei and Wang, Qiang and Xiao, Liuling and Xiong, Wei and Xian, Miao and Su, Pan and Yang, Maojie and Zhang, Chuanchao and Li, Yabo and Zhong, Ling and Ganguly, Siddhartha and Zu, Youli and Yi, Qing},
  title = {Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008145}
}
Kostenlos starten →